In order to determine if our observations result in an upregulated MITF activity, we chose to assay the tyrosinase activity as well as the melanin production rate in GH treated or GHR-blocked melanoma cells, in presence of multiple classes of anticancer drugs. The gene discussed is GH1; the disease is melanoma.